Exor increases its stake in the French company bioMérieux to 8.53 per cent
Institut Mérieux will remain the majority shareholder in the French biotech company, holding 55.24 per cent of the share capital and 68.67 per cent of the voting rights.
Exor has increased its direct stake in bioMérieux, a company specialising in in vitro diagnostics, from 3.87 per cent to 8.53 per cent. The company, which is owned by the heirs of the Agnelli family, made the announcement, stating that it will receive the bioMérieux shares through a reduction in the stake held by the Institut Mérieux. In return, the Institut Mérieux will receive a portion of its own shares held by Exor.
Following the completion of the transaction, scheduled for December 2026, subject to the creditors’ objection period and formal approval by the shareholders of Institut Mérieux, Exor will hold 8.53 per cent of bioMérieux’s share capital and 5.35 per cent of its voting rights. Institut Mérieux will remain the majority shareholder of the French biotech company, holding 55.24 per cent of the share capital and 68.67 per cent of the voting rights. Furthermore, following the transaction, Exor will hold 5.02 per cent of the share capital of Institut Mérieux and 2.58 per cent of its voting rights.
“Less than two years after its initial investment in the company, Exor’s decision to increase its stake in bioMérieux is a strong sign of confidence in our strategy, our growth potential and our ability to create value. We deeply appreciate this long-term perspective. The Institut Mérieux will remain our majority shareholder. The stability and support provided by the Mérieux family’s ownership have always been a strength for bioMérieux and are particularly valuable in the current changing environment,” comments Pierre Boulud, CEO of bioMérieux.
Exor’s involvement
Exor has been a shareholder in the Institut Mérieux since 2022 and a direct shareholder in bioMérieux since 2025. The board of directors of bioMérieux will propose the appointment of Benoît Ribadeau-Dumas as Exor’s representative at the next annual general meeting. Ribadeau-Dumas is already a member of the Institut Mérieux board and a non-voting observer on the bioMérieux board. The governance structure of the Institut Mérieux will remain unchanged.
‘Since 2022, our investment in the Institut Mérieux has given us first-hand insight into the Mérieux family’s entrepreneurial culture and their commitment to public health. We reaffirm our commitment as a shareholder in the Group and are delighted to further increase our stake in bioMérieux, a company we know well, which we deeply value for its leadership in the diagnostics sector and which we intend to support over the long term,” said John Elkann, Chief Executive of Exor.


